Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance
Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.
Allergy Therapeutics, a pharmaceutical company specialized in allergy vaccination, announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.
During the past seven years, more than £10 million has been invested in the upgrade of this injectables facility. The facility has the capacity to further increase output and operating efficiencies, with more than 210,000 allergy vaccines and diagnostic tests manufactured at this site each year and over 95% of sales made overseas. In the past 12 months, products have been supplied to new markets including the Baltic States and New Zealand.
Allergy Therapeutics employs around 200 people in Worthing and is proud of it trading heritage, spanning nearly 80 years.
Source: Allergy Therapeutics
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
